JAJoseph C. Anderson

Joseph C. Anderson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joseph C. Anderson has a total of 154 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Colonoscopy outcomes after positive multi-target stool DNA testing in patients with and without a prior normal colonoscopy: Data from the New Hampshire Colonoscopy Registry

    by Joseph C. Anderson, William M. Hisey, Christina M. Robinson, Paul J. Limburg, Mallik Greene, Lynn F. Butterly

    Background and aims: Patients who previously had a normal colonoscopy may subsequently undergo colorectal cancer (CRC) screening with multitarget stool DNA (mt-sDNA) testing. The yield of advanced neoplasia following a positive mt-sDNA test in this subgroup is not well defined. We compared colonoscopy outcomes after positive mt-sDNA tests in patients with and without a prior normal colonoscopy. Methods: We conducted a registry-based analysis using data from the population-based New Hampshire Colonoscopy Registry (NHCR). The primary outcome was an ordered four-level categorical variable reflecting colonoscopy findings: CRC, advanced colorectal neoplasia, non-advanced colorectal neoplasia, and no neoplasia. Ordinal logistic regression models were used to evaluate the association between prior normal colonoscopy and severity of findings. Results: Patients with a prior normal colonoscopy (n=739) were approximately half as likely to have more advanced findings compared with patients without a prior colonoscopy (n=994); prior normal colonoscopy was associated with lower odds of more advanced versus less advanced outcomes (OR 0.51; 95% CI 0.41–0.62; P < 0.001). However, the absolute prevalence of advanced colorectal neoplasia among patients with a previous colonoscopy remained substantial (19.1%; 95% CI 16.3–22.1%). Conclusions: Although prior normal colonoscopy is associated with lower odds of advanced findings after a positive mt-sDNA test, the residual prevalence of advanced neoplasia remains clinically meaningful. Regardless of prior screening history, there is a high yield of neoplasia, which could be attributed in part due to missed lesions on the prior colonoscopy. Our data provide potential benchmarks for expected lesion yield in this population.

  • Association Between Index Adenomas and Advanced Neoplasia at Third Surveillance Colonoscopy: Data From the New Hampshire Colonoscopy Registry

    by Joseph C. Anderson, Obaida Dairi, Darius Javidi, Todd MacKenzie, Christopher I. Amos, Christina M. Robinson, Lynn F. Butterly

    BACKGROUND: Owing to a lack of data, the United States Multi-Society Task Force does not provide guidance for the third surveillance examination for adenomas detected on index colonoscopy. Our aim was to assess advanced outcome risk at third surveillance in patients with index adenomas. METHODS: We included patients from the New Hampshire Colonoscopy Registry with no genetic syndromes, inflammatory bowel disease, those with first degree relative with colorectal cancer younger than 50 years of age, adequate bowel preparation, no colorectal cancer on index, and with 3 follow-up colonoscopies each >12 months apart. Only patients with normal or low-risk findings (1–2 small tubular adenomas/sessile serrated polyps) on first and second surveillance examinations were included. Individuals were stratified by index adenomas: no adenomas, 1–2 nonadvanced adenomas (NAA), 3–4 NAA, 5+NAA and advanced adenomas. A Poisson model adjusting for age, sex, index serrated polyps, endoscopist adenoma detection rates, and months to follow-up examination (offset variable) predicting advanced neoplasia on third surveillance was performed. RESULTS: Patients (n = 1,021) with an advanced adenomas on index were found to have a statistically significant increased risk of advanced neoplasia on third surveillance as compared with those patients with no adenomas (adjusted rate ratio = 3.96 [95% CI: 1.96–7.98]). In addition, after adjusting for endoscopists adenoma detection rates, the risk ratio (RR) was still statistically higher for this group (RR = 3.00 [95% confidence interval: 1.20–7.48]). DISCUSSION: Our data suggest that those with an advanced adenomas on index examination continue to have a statistically significant increased risk of advanced neoplasia on third surveillance. This finding supports close surveillance in patients with these lesions.

  • Open Access

    Yield of Synchronous Adenomas and Serrated Polyps in Patients With Positive Stool Tests (mt‐ sDNA or FIT ): Data From the New Hampshire Colonoscopy Registry

    by Joseph C. Anderson, William M. Hisey, Christina M. Robinson, Paul J. Limburg, Bonny L. Kneedler, Lynn F. Butterly

    Background and Aims: Patients with synchronous conventional adenomas and serrated polyps are at increased risk for metachronous neoplasia. We used New Hampshire Colonoscopy Registry data to examine the prevalence, pathway, and severity of synchronous lesions detected on colonoscopy after positive multi‐target‐stool DNA (mt‐sDNA) or Fecal Immunochemical Tests (FIT), compared to colonoscopies without prior stool test. Methods: We estimated the risk of synchronous conventional adenomas and serrated polyps relative to no lesions, adenomas only, and serrated polyps only, across the three study cohorts using multinomial logistic regression. Results: We included 1089 mt‐sDNA+ patients, 436 FIT+ patients, and 43 379 patients with screening colonoscopy only without previous stool test. Patients with mt‐sDNA+ tests had a higher risk of synchronous lesions compared to FIT+ patients (OR = 2.34; 95% CI: 1.70–3.28) and colonoscopy‐only patients (OR = 2.92; 95% CI: 2.50–3.40). Mt‐sDNA+ patients also had significantly higher risks of serrated polyps versus no polyps (RRR = 2.92; 95% CI: 2.39–3.58) and synchronous polyps versus adenomas alone (RRR = 2.00; 95% CI: 1.67–2.4) compared to colonoscopy‐only patients; no such differences were found in the FIT+/colonoscopy‐only comparison. Most mt‐sDNA+ and FIT+ patients with synchronous lesions had at least one advanced lesion, while the majority of colonoscopy‐only patients with synchronous lesions had no advanced lesion. Conclusions: The yield of synchronous conventional adenomas and serrated polyps is higher in patients with positive mt‐sDNA tests compared to FIT+ or colonoscopy‐only patients, likely due in part to the higher yield of serrated polyps in mt‐sDNA+ patients, which persists even among patients with adenomas.

  • Outcomes and Characteristics Across Age Groups of Patients with Positive MT-sDNA Stool Tests: Data from the New Hampshire Colonoscopy Registry

    by Joseph C. Anderson, William M. Hisey, Christina M. Robinson, Paul J. Limburg, Mallik Greene, Lynn F. Butterly

    Stool testing is a colorectal cancer (CRC) screening option for adults 45 years and older. Our aim was to examine characteristics and outcomes across age groups of patients who underwent colonoscopy following a positive multitarget stool DNA (mt-sDNA) test, compared to older age groups. We examined several outcomes reflecting both adenomatous and serrated pathways, including: any adenoma, clinically relevant serrated polyps (CRSPs, defined as sessile serrated polyps, traditional serrated adenomas, or hyperplastic polyps ≥ 1 cm) and advanced adenomas (AA, defined as any villous or tubulovillous adenomas, or tubular adenomas > 1 cm). Logistic regression models assessed the association between continuous age and each outcome, adjusting for patient sex and other relevant covariates. The yield of advanced adenomas and CRSPs were equally high across all age groups, including the youngest group; we found no difference in the yield of AAs (OR = 0.99;95%CI:0.91-1.07) or CRSPs (OR = 0.95%CI:0.88-1.03) with increasing age. In contrast, the odds of any adenoma increased significantly with age (OR = 1.17;95%CI:1.09-1.26). The yield of clinically significant polyps at colonoscopy following a positive multitarget stool DNA (mt-sDNA) test was similarly high across age groups. These findings suggest that mt-sDNA screening provides comparable clinical benefit across all ages of screening-eligible populations. The consistently high detection of advanced polyps across age groups likely reflects the strong positive predictive value of mt-sDNA testing.

  • Association Between Index Adenomas and Advanced Findings at Third Colonoscopy: Data From the New Hampshire Colonoscopy Registry

    by Darius J. Javidi, Obaida Dairi, Todd A. MacKenzie, Christopher I. Amos, Lynn F. Butterly, Joseph C. Anderson


  • Optimal Management of Conventional Adenomas in 2026

    by Bianca Do Thakkar, Rachael Do Hagen, Joseph C. Anderson

    Adenomas are the most common precancerous colorectal lesions detected during colonoscopy. The techniques, endoscopic tools, and recommendations for detection, resection, and surveillance continue to change. This review summarizes current practice regarding detection and resection as well as national and international guidelines for screening, surveillance intervals, and recommended resection techniques, while highlighting areas where recommendations diverge or remain uncertain. We discuss key controversies shaping clinical decision-making, including topics such as the use of all-examination versus screening-specific adenoma detection rate (ADR) thresholds, the impact of computer-aided polyp detection (CADe) on quality benchmarks, and the debated significance of villous features or high-grade dysplasia in guiding follow-up intensity. We use the calendar year 2026 as the reference starting point for optimal adenoma management. In our review, we integrate current guideline recommendations with emerging evidence and ongoing shifts in endoscopic practice, rather than relying on anticipated formal guideline updates. By synthesizing established standards with new data and advancing technologies, this review provides a practical overview to support gastroenterologists in optimizing adenoma management and applying guideline-based care.

  • Risk Factors of Proximal and Distal Advanced Colorectal Conventional and Serrated Neoplasia in Adults Younger Than 50 Years of Age

    by Darius J. Javidi, Lynn F. Butterly, Christopher I. Amos, Todd A. Mackenzie, Christina M. Robinson, Joseph C. Anderson

    INTRODUCTION: Colorectal cancer (CRC) has increased in adults younger than 50 years of age, particularly in the distal colon. Data examining the risk factors of advanced colorectal neoplasia in young adults as stratified by anatomic location have important implications for screening and risk modification. METHODS: We conducted a cross-sectional analysis of data from New Hampshire Colonoscopy Registry participants younger than 50 years of age. We developed an average-risk equivalent sample by excluding patients with IBD, genetic syndromes, and those with indications predictive of colorectal neoplasia such as anemia or hematochezia. Our outcomes were left-sided and right-sided advanced conventional neoplasia (≥1 cm; villous or high grade dysplasia), advanced serrated neoplasia (>1 cm or with dysplasia), and having synchronous advanced neoplasia and sessile serrated polyps/lesions. RESULTS: We included 14,369 patients, younger than 50 years at colonoscopy. Increased risk of left-sided advanced neoplasia was observed with current smoking (odds ratio [OR] 2.14), male sex (OR 1.66), older age (OR 1.07), and higher body mass index (BMI) (OR 1.02). Right-sided advanced neoplasia was associated with smoking (OR 1.71), family history of CRC (OR 1.62), older age (OR 1.07), and higher BMI (OR 1.03). Left advanced serrated neoplasia was associated with older age (OR 1.08), and higher BMI (OR 1.05). Left-sided synchronous lesions were associated with smoking (OR 2.33), older age (OR 1.08), and higher BMI (OR 1.04). Right-sided synchronous lesions were associated with family history of CRC (OR 1.67). The lower bound of the 95% CI for each OR was >1. DISCUSSION: We identified modifiable risk factors including current smoking and higher BMI in young adults with right and left-sided colorectal polyps. Older age, male sex, and family history were nonmodifiable predictors. These data can help to inform screening and prevention of CRC in young adults.


  • Higher Sessile Serrated Lesion Detection Rates Calculated Using All Examinations Are Associated With Lower Risk for Postcolonoscopy Colorectal Cancer: Data From the New Hampshire Colonoscopy Registry

    by Rachael Hagen, Douglas K. Rex, Todd A. MacKenzie, Christopher I. Amos, Lynn F. Butterly, Joseph C. Anderson

    INTRODUCTION: Calculating detection rates using data from colonoscopies for all indications, rather than screening examinations, is simpler and can mitigate gaming by endoscopists. We hypothesized that calculating sessile serrated lesion detection rates (SSLDR-A) using all examinations may also be a quality metric for predicting postcolonoscopy colorectal cancer (PCCRC) risk. METHODS: The cohort included New Hampshire Colonoscopy Registry 115,762 patients with an index colonoscopy. The primary outcome was PCCRC, defined as colorectal cancer (CRC) diagnosed ≥6 months after the index colonoscopy. The exposure variables were endoscopist-specific SSLDR-A (using all examinations) and SSLDR-S (using screening examinations), stratified into quintiles. Cox regression was used to model the hazard of PCCRC on SSLDR, adjusting for relevant covariates, such as patient age and sex. RESULTS: There were 177 PCCRCs diagnosed in 115,762 patients with index colonoscopies. Higher SSLDR-A and SSLDR-S rates were associated with lower PCCRC risks. After adjusting for covariates, we observed that higher SSLDR-A rates were associated with lower hazard ratios (HRs) as compared with the reference group (SSLDR-A: <1.5%; HR = 1.0 vs SSLDR-A: 1.5% to <3.0%; HR = 0.53, 95% CI 0.35–0.79; SSLDR-A: 3.0% to <5.0%; HR = 0.59, 95% CI 0.38–0.92; SSLDR: 5.0% to <8.0%; HR = 0.44, 95% CI 0.28–0.70; and SSLDR: 8.0+%; HR = 0.20, 95% CI 0.08–0.46). The highest quintile of SSLDR-A (8.0%+) (HR = 0.20, 95% CI 0.08–0.46) and SSLDR-S (8.0%+) (HR = 0.20, 95% CI 0.09–0.44) provided similar protection from PCCRC. DISCUSSION: These findings demonstrate that colonoscopies performed by endoscopists with higher SSLDR-A are associated with a lower risk of PCCRC, validating SSLDR-A as a quality metric. Furthermore, our data suggest that endoscopists should aim for an SSLDR-A of 6% and have an aspirational SSLDR-A of 8.0% or higher.


  • Association Between Serrated Polyps on Index Examination and Advanced Findings Detected on the Second Surveillance Colonoscopy: Data From the New Hampshire Colonoscopy Registry

    by Obaida Dairi, Joseph C. Anderson, Christopher I. Amos, William Hisey, Todd A. Mackenzie, Lynn F. Butterly, Anne I. Hahn, Iris Lansdorp-Vogelaar, Christina M. Robinson, Amitabh Srivastava, et al.